In preclinical work recently published in Nature Communications, Fred Hutchinson Cancer Center scientists used a genetic “chain reaction” to transform herpes simplex virus DNA during an HSV infection.
Wugen Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, announced it will initiate a phase II study in the first quarter of 2025 for the company’s potential first-in-class, investigational, anti-CD7 CAR T-cell therapy, WU-CART-007, in patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
A new report says those considering PSA screening need such quantitative information on risks and benefits of treatment if they are to make truly informed decisions. Yet leading guidelines do not provide specific estimates of risk. The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after... […]
Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib (Jakafi) to standard tyrosine kinase inhibitor treatment for patients with chronic-phase chronic myeloid leukemia significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. Results were presented at the European School of Haematology’s 26th Annual John... […]
Quitting smoking within six months after a cancer diagnosis adds an average of two years to a patient’s life, according to a study published inJAMA Oncology, With this information in hand, all cancer centers have an obligation to offer evidence-based smoking cessation to all patients, said Graham Warren, vice-chair for Research in the Department of... […]
While pancreatic cancer rates are rising in people under age 50, a new survey conducted by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute shows that most people continue to believe that pancreatic disease affects only elderly people—and that there is nothing they can do to... […]
For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk. By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that... […]
An international, multidisciplinary team of leading neuro-oncology researchers and clinicians has released new recommendations for good clinical practice—a set of guidelines that helps ensure clinical trial results are reliable, and patients are protected—regarding the use of artificial intelligence methods to more accurately diagnose, monitor, and treat brain cancer patients. The team recently published two companion... […]
New preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells, were presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The meeting is taking place both virtually and at the George R. Brown Convention Center in... […]
Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they’ve escaped the low-oxygen regions of a tumor. Each is a potential therapeutic target to stop cancer recurrence, and one—MUC1—is already in clinical trials. The research was published online Sept. 28 in... […]
